Pegaptanib [Macugen, OSI pharmaceuticals, Pfizer] is an aptamer targeting vascular endothelial growth factor (VEGF165) and was approved by the FDA for the treatment of AMD of the retina. The gene discussed is VEGFA; the disease is age-related macular degeneration.